October 22-23, 2021 – Virtual Congress
Future of Psychiatry: Role of TechnologyXin-Min Li, Canada Advances in psychotherapy/pharmacotherapy enhanced neuromodulation in treating major depressive disorderYanbo Zhang, Canada TBCYuan-Hwa Chou, Taiwan Pipeline Medications for SchizophreniaLin Shih Ku Chairperson: Lin Shih Ku, Taiwan
Efficacy and safety of adjunctive aripiprazole, metformin and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trialsHan Qi, China Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s diseaseYuan Yuan Wang, UK Efficacy and safety of traditional Chinese herbal medicine for antipsychotic-related constipation: a systematic review and meta-analysis of randomized controlled …
Depression is a complex and often chronic illness. Improving health outcomes in depression begins with improving characterization of the illness in those affected. Ecological momentary assessment (EMA) provides opportunity for passive and ambient collection of data that EMA devices suggest can determine whether a patient is depressed or not. Notwithstanding the availability of multiple app-based …
In 2009 we published one of the earlier network meta-analyses (NMA) of 12 new generation antidepressants in the acute phase treatment of depression 1. In 2018 we expanded and updated this NMA by including five more new generation antidepressants and four old antidepressants (522 trials, 116 477 participants) 2. The major difficulty in these endeavors …
Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depressionRoger Ho, Singapore Therapeutic strategy in schizophrenia by targeting neuroinflammationKristian Liaury, Indonesia Immune markers in psychiatric disorders: leptin-modulated corticostriatal circuitry in bipolar I and bipolar II disordersPo See Chen, Taiwan Inflammatory markers and Mood Disorders: Proinflammatory Cytokine Dysregulation, Cognitive Dysfunction, and Reduced …
“Treatment resistance” is a definition that does not belong to the classification system, because it depends on the availability of suitable therapies at a given point in history. However, it has regulatory implications, and it may be useful for clinical practice. Treatment resistance is quite well defined in the field of depression, but not so …
Announcement of Oral / Poster Prize Awards (Ho Su Hui, Cyrus) Closing Remarks (Roger Ho Chun Man) Invitation to 8th AsCNP Congress 2023, China (Tianmei Si, President-Elect, AsCNP)
Polypharmacy in Bipolar disorder: Findings from REAP Bipolar Disorder studyVie Cheong Thong, Malaysia Clinical use of mood stabilizers in REAP Study – Focus on clinical symptoms of bipolar disorderIsa Multazam Noor, Indonesia Clinical use of mood stabilizers in Asian patients: summary from REAP-BD and MS studiesPornjira Pariwatcharakul, Thailand Research on Asian Psychotropic Prescription Patterns on …
Hypermethylation of RUFY1 associated with high risks of schizophrenia and poor treatment responses in Han ChineseWeihua Yue, China Frontal-posterior functional imbalance and aberrant function developmental patterns in schizophreniaFei Wang, China The role of white blood cell counts in metabolic changes and clinical symptom improvement after antipsychotics in patients with schizophrenia: evidence from a large Chinese …
Bipolar disorder is a complex psychiatric condition with pleomorphic presentations, varied course and high comorbidity. While several options are available for treating mania and preventing mania, many challenges remain in providing optimal outcomes for patients with bipolar disorder. For instance, treatment options continue to be limited for treating acute depressive symptoms in patients with bipolar …